In Reply Drs Rao and Dlouhy mention several valid points regarding the bottlenecks of iPSC derivation and suggest that direct reprogramming to induced cardiomyocytes (iCMs) may be a more cost-effective, efficient, and safe alternative. Transdifferentiation to iCMs presents both advantages and disadvantages compared with the use of iPSC-derived cardiomyocytes. We think that both of these methods offer significant potential for the clinical treatment of cardiac disease in addition to cardiovascular drug discovery.
Mordwinkin NM, Lee AS, Wu JC. Stem Cells and Cardiovascular Drug Development—Reply. JAMA. 2014;311(10):1070-1071. doi:10.1001/jama.2014.634